Search

Your search keyword '"Girschikofsky, Michael"' showing total 6 results
Start Over Author "Girschikofsky, Michael" Publisher wiley-blackwell
6 results on '"Girschikofsky, Michael"'

1. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT

Author

Pleyer, Lisa, Vaisband, Marc, Drost, Manuel, Pfeilstöcker, Michael, Stauder, Reinhard, Heibl, Sonja, Sill, Heinz, Girschikofsky, Michael, Stampfl‐Mattersberger, Margarete, Pichler, Angelika, Hartmann, Bernd, Petzer, Andreas, Schreder, Martin, Schmitt, Clemens A., Vallet, Sonia, Melchardt, Thomas, Zebisch, Armin, Pichler, Petra, Zaborsky, Nadja, and Machherndl‐Spandl, Sigrid

Published
2023
Full Text
View/download PDF

3. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial.

Author

Egle, Alexander, Melchardt, Thomas, Obrtlíková, Petra, Smolej, Lukáš, Kozák, Tomáš, Steurer, Michael, Andel, Johannes, Burgstaller, Sonja, Mikušková, Eva, Gercheva, Liana, Nösslinger, Thomas, Papajík, Tomáš, Ladická, Miriam, Girschikofsky, Michael, Hrubiško, Mikuláš, Jäger, Ulrich, Voskova, Daniela, Pecherstorfer, Martin, Králiková, Eva, and Burcoveanu, Christina

Subjects
RITUXIMAB, CHRONIC lymphocytic leukemia, SUBGROUP analysis (Experimental design), OBESITY, WEIGHT loss
Abstract

No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab‐containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375 mg/m2 q3 months for 2 years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non‐obese, P = 0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P = 0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39 months median PFS, P = 0.03). However, in the rituximab maintenance group the outcome for obese vs non‐obese was not different (P = 0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

5. Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.

Author

Sperr, Wolfgang R., Herndlhofer, Susanne, Gleixner, Karoline, Girschikofsky, Michael, Weltermann, Ansgar, Machherndl-Spandl, Sigrid, Sliwa, Thamer, Poehnl, Rainer, Buxhofer-Ausch, Veronika, Strecker, Karin, Hoermann, Gregor, Knoebl, Paul, Jaeger, Ulrich, Geissler, Klaus, Kundi, Michael, and Valent, Peter

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results